JP2023522154A - インフルエンザワクチン - Google Patents

インフルエンザワクチン Download PDF

Info

Publication number
JP2023522154A
JP2023522154A JP2022560280A JP2022560280A JP2023522154A JP 2023522154 A JP2023522154 A JP 2023522154A JP 2022560280 A JP2022560280 A JP 2022560280A JP 2022560280 A JP2022560280 A JP 2022560280A JP 2023522154 A JP2023522154 A JP 2023522154A
Authority
JP
Japan
Prior art keywords
amino acid
seq
polypeptide
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522154A5 (enExample
Inventor
ジョナサン ルーク ヒーニー，
スネハ ビシュワナス，
ジョージ カーネル，
デイビッド ウェルズ，
マッテオ フェラーリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chancellor masters And Scholars Of University Of Cambridge
Original Assignee
Chancellor masters And Scholars Of University Of Cambridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chancellor masters And Scholars Of University Of Cambridge filed Critical Chancellor masters And Scholars Of University Of Cambridge
Publication of JP2023522154A publication Critical patent/JP2023522154A/ja
Publication of JP2023522154A5 publication Critical patent/JP2023522154A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022560280A 2020-04-01 2021-04-01 インフルエンザワクチン Pending JP2023522154A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2004825.2A GB202004825D0 (en) 2020-04-01 2020-04-01 Influenza vaccines
GB2004825.2 2020-04-01
PCT/GB2021/050825 WO2021198701A1 (en) 2020-04-01 2021-04-01 Influenza vaccines

Publications (2)

Publication Number Publication Date
JP2023522154A true JP2023522154A (ja) 2023-05-29
JP2023522154A5 JP2023522154A5 (enExample) 2024-05-08

Family

ID=70553229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560280A Pending JP2023522154A (ja) 2020-04-01 2021-04-01 インフルエンザワクチン

Country Status (8)

Country Link
US (1) US20230149530A1 (enExample)
EP (1) EP4126026A1 (enExample)
JP (1) JP2023522154A (enExample)
CN (1) CN116457005A (enExample)
AU (1) AU2021250704A1 (enExample)
CA (1) CA3179035A1 (enExample)
GB (1) GB202004825D0 (enExample)
WO (1) WO2021198701A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114395052B (zh) * 2022-03-25 2022-07-22 北京中海生物科技有限公司 一种重组禽流感三价疫苗及其制备方法与应用
GB202315888D0 (en) * 2023-10-17 2023-11-29 Diosynvax Ltd Influenza vaccines
CN117912568B (zh) * 2024-01-05 2024-08-06 中山大学 H9n2亚型禽流感毒株抗原性快速鉴别方法及装置
WO2025179103A1 (en) * 2024-02-23 2025-08-28 University Of Georgia Research Foundation, Inc. Pentavalent and octavalent influenza virus immunogens, compositions and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102140441A (zh) * 2010-11-04 2011-08-03 高福 基于减毒痘苗病毒天坛株为载体的禽流感疫苗
WO2012036993A1 (en) * 2010-09-14 2012-03-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
WO2013075266A1 (en) * 2011-11-23 2013-05-30 Vacdiagn Biotechnology Co., Ltd. Immune methods against influenza viruses and combinatorial vaccines thereof
WO2015099609A1 (en) * 2013-12-23 2015-07-02 Temasek Life Sciences Laboratory Limited Monovalent h5 vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083533A1 (es) * 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
CA2863949C (en) * 2012-02-13 2021-06-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
WO2013185177A1 (en) * 2012-06-12 2013-12-19 Csl Limited Influenza vaccine
US20140286981A1 (en) * 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
KR102463632B1 (ko) * 2014-07-10 2022-11-03 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
WO2016100926A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
EP3463447A4 (en) * 2016-06-03 2020-05-27 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS PROTECTION Vaccines
EP4412644A1 (en) * 2021-10-06 2024-08-14 DIOSynVax Ltd Influenza vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012036993A1 (en) * 2010-09-14 2012-03-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
CN102140441A (zh) * 2010-11-04 2011-08-03 高福 基于减毒痘苗病毒天坛株为载体的禽流感疫苗
WO2013075266A1 (en) * 2011-11-23 2013-05-30 Vacdiagn Biotechnology Co., Ltd. Immune methods against influenza viruses and combinatorial vaccines thereof
WO2015099609A1 (en) * 2013-12-23 2015-07-02 Temasek Life Sciences Laboratory Limited Monovalent h5 vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK，ACCESSION NO. ADM33956，[ONLINE], JPN6025012505, 30 August 2010 (2010-08-30), ISSN: 0005561048 *
DATABASE GENBANK，ACCESSION NO. AEQ50042，[ONLINE], JPN6025012507, 29 November 2011 (2011-11-29), ISSN: 0005561050 *
DATABASE GENBANK，ACCESSION NO. AKH14272，[ONLINE], JPN6025012506, 19 May 2015 (2015-05-19), ISSN: 0005561049 *
J. VIROL., vol. 84, no. 17, JPN6025012504, 2010, pages 8389 - 8397, ISSN: 0005561047 *
VIRUS GENES, vol. 44, JPN6025012503, 2012, pages 247 - 252, ISSN: 0005561046 *

Also Published As

Publication number Publication date
CN116457005A (zh) 2023-07-18
GB202004825D0 (en) 2020-05-13
US20230149530A1 (en) 2023-05-18
CA3179035A1 (en) 2021-10-07
WO2021198701A1 (en) 2021-10-07
AU2021250704A1 (en) 2022-12-08
EP4126026A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP7655849B2 (ja) ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
JP6294828B2 (ja) インフルエンザウイルスワクチンおよびその使用
RU2612900C2 (ru) Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
US10729758B2 (en) Broadly reactive mosaic peptide for influenza vaccine
RU2653756C2 (ru) Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2
CN101484466A (zh) 针对流感病毒的抗病毒剂和疫苗
WO2021198701A1 (en) Influenza vaccines
JP2024537250A (ja) インフルエンザワクチン
WO2021220246A1 (en) Recombinant sars-cov-2 polypeptides and uses
JP2023052092A (ja) 免疫原性組成物
WO2019076218A1 (zh) H3n2亚型流感病毒血凝素蛋白的突变体及其应用
WO2011024748A1 (ja) インフルエンザm2由来の改変ペプチドワクチン
US20070122430A1 (en) Influenza vaccine compositions and methods of use thereof
CN104797594A (zh) 计算优化的广泛反应性h1n1流感抗原
JP2018052953A (ja) インフルエンザウイルスワクチンおよびその使用
Chen et al. Comparative analysis of antibody induction and protection against influenza virus infection by DNA immunization with HA, HAe, and HA1 in mice
HK40090677A (en) Influenza vaccines
CN118922204A (zh) 流感疫苗
US12239700B2 (en) Identification of variable influenza residues and uses thereof
CN113227360A (zh) 具有新型流感病毒来源的血凝素蛋白基因的DIs株来源的重组牛痘病毒
EP4574168A1 (en) Prime-boost immunization against influenza
WO2026074282A1 (en) Influenza vaccines
WO2025083412A2 (en) Influenza vaccines
WO2025083402A1 (en) Coronavirus vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260706